Poor
Not Aligned
Patient Risk:
High
Summary
Most statements provided are not supported by the supplied FDA label excerpts (boxed warning/all-cause mortality and related sections). Only the general boxed-warning concept of increased all-cause mortality with a 0.6% risk difference and reserving use for unsuitable alternatives is supported; the remaining efficacy/indication, mechanism, and side-effect claims cannot be verified against the provided label text and include duration-based monitoring claims not present in the excerpts.
Category Scores
Accurate Statements
Prolonged use of tigecycline may increase the risk of gastrointestinal side effects including diarrhea, nausea, and vomiting.
No supporting text in the supplied label excerpts (BOXED WARNING/5.1/5.2/1.4/6.1) for gastrointestinal side effects or duration relationship.
Patients receiving tigecycline for more than 7 days were more likely to experience gastrointestinal side effects than those receiving shorter-duration treatment.
No supporting text in the supplied label excerpts.
Unsupported Statements
Tigecycline is a glycylcycline antibiotic.
Not supported by the provided label excerpts.
Tigecycline works by inhibiting protein synthesis in bacteria.
Not supported by the provided label excerpts.
Tigecycline was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI).
No approval year or indication listing in the provided excerpts.
Tigecycline was approved by the FDA in 2005 for the treatment of complicated intra-abdominal infections (cIAI).
No approval year or indication listing in the provided excerpts.
Tigecycline was approved by the FDA in 2005 for the treatment of community-acquired bacterial pneumonia (CABP).
No approval year or indication listing in the provided excerpts.
Common side effects of tigecycline include nausea and vomiting.
No adverse reaction frequency/“common side effects” statements in the provided excerpts.
Common side effects of tigecycline include diarrhea.
No adverse reaction frequency/“common side effects” statements in the provided excerpts.
Common side effects of tigecycline include abdominal pain.
No adverse reaction frequency/“common side effects” statements in the provided excerpts.
Common side effects of tigecycline include constipation.
No adverse reaction frequency/“common side effects” statements in the provided excerpts.
Common side effects of tigecycline include headache.
No adverse reaction frequency/“common side effects” statements in the provided excerpts.
Common side effects of tigecycline include dizziness.
No adverse reaction frequency/“common side effects” statements in the provided excerpts.
Prolonged use of tigecycline may increase the risk of gastrointestinal side effects including diarrhea, nausea, and vomiting.
No gastrointestinal adverse-effect risk statements or duration relationship in the provided excerpts.
Patients receiving tigecycline for more than 7 days were more likely to experience gastrointestinal side effects than those receiving shorter-duration treatment.
No duration threshold data in the provided excerpts.
Tigecycline's mechanism of action may disrupt the balance of gut bacteria.
Not addressed in the provided excerpts.
Disruption of the gut bacteria by tigecycline can lead to changes in the gut microbiome.
Not addressed in the provided excerpts.
Changes in the gut microbiome can result in gastrointestinal symptoms including diarrhea, abdominal pain, and nausea.
Not addressed in the provided excerpts.
A case report described a patient who developed severe diarrhea and abdominal pain after receiving tigecycline for 14 days.
Not addressed in the provided excerpts.
Patients receiving tigecycline for more than 10 days were more likely to experience gastrointestinal side effects.
No duration threshold data in the provided excerpts.
Healthcare providers should monitor patients closely for gastrointestinal side effects when using tigecycline.
No monitoring instruction for gastrointestinal side effects in the provided excerpts.
Healthcare providers should use tigecycline judiciously and for the shortest duration necessary.
No such general instruction in the provided excerpts.
Healthcare providers should consider alternative antibiotics for patients with pre-existing gastrointestinal conditions.
No guidance about pre-existing gastrointestinal conditions in the provided excerpts.
Contradictions
Low
AI Statement
Tigecycline was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI).
Label Reference
Provided label excerpts do not state approval year or indication approval date.
Important Omissions
The provided response set does not include the boxed warning content about increased all-cause mortality (risk difference 0.6% [95% CI 0.1, 1.2]) and the reservation statement for use when alternative treatments are not suitable, which is the only clearly label-anchored warning in the supplied excerpts.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The bulk of the response consists of GI mechanism/duration/“common side effects” and monitoring recommendations that are not supported by the supplied boxed warning/all-cause mortality label excerpts, and the key boxed-warning reserve-for-alternatives instruction is omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are unsupported by the provided FDA label excerpts; key boxed-warning language and reservation guidance are omitted.
Suggested Improvement
Limit evaluable statements to the supplied label text (BOXED WARNING/5.1/5.2/1.4/6.1). Specifically include the boxed warning for increased all-cause mortality (0.6% risk difference [95% CI 0.1, 1.2]) and the instruction to reserve use when alternative treatments are not suitable; remove or qualify all GI side-effect frequency, mechanism-of-gut-microbiome, duration thresholds, case report details, and monitoring/alternative-antibiotic guidance unless supported by the label sections provided.